TY - JOUR
AU - Sokolowska, Milena
AU - Rovati, G. Enrico
AU - Diamant, Zuzana
AU - Untersmayr, Eva
AU - Schwarze, Jürgen
AU - Lukasik, Zuzanna M.
AU - Sava, Florentina
AU - Angelina, Alba
AU - Palomares, Oscar
AU - Akdis, Cezmi A.
AU - O'Mahony, Liam
AU - Jesenak, Milos
AU - Pfaar, Oliver
AU - Torres, María José
AU - Sanak, Marek
AU - Dahlén, Sven-Erik
AU - Woszczek, Grzegorz
PY - 2022
DA - February
TI - Effects of non‐steroidal anti‐inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses. EAACI task force on eicosanoids consensus report in times of COVID‐19
JO - Allergy
DO - https://doi.org/10.1111/all.15258
AB - Non-steroidal anti-inflammatory drugs (NSAIDs) and other eicosanoid pathway modifiers are among the most ubiquitously used medications in the general population. Their broad anti-inflammatory, antipyretic and analgesic effects are applied against symptoms of respiratory infections, including SARS-CoV-2, as well as in other acute and chronic inflammatory diseases that often coexist with allergy and asthma. However, the current pandemic of COVID-19 also revealed the gaps in our understanding of their mechanism of action, selectivity and interactions not only during viral infections and inflammation, but also in asthma exacerbations, uncontrolled allergic inflammation, and NSAIDs-exacerbated respiratory disease (NERD). In this context, the consensus report summarises currently available knowledge, novel discoveries and controversies regarding the use of NSAIDs in COVID-19, and the role of NSAIDs in asthma and viral asthma exacerbations. We also describe here novel mechanisms of action of leukotriene receptor antagonists (LTRAs), outline how to predict responses to LTRA therapy and discuss a potential role of LTRA therapy in COVID-19 treatment. Moreover, we discuss interactions of novel T2 biologicals and other eicosanoid pathway modifiers on the horizon, such as prostaglandin D2 antagonists and cannabinoids, with eicosanoid pathways, in context of viral infections and exacerbations of asthma and allergic diseases. Finally, we identify and summarise the major knowledge gaps and unmet needs in current eicosanoid research.
PB - Wiley
UR - https://www.research.ed.ac.uk/en/publications/8d1d3d01-82b5-4e7f-9b6b-269d2024ca07
KW - Coronavirus (COVID-19)
ER